Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $84.84, for a total value of $466,620.00. Following the completion of the sale, the insider owned 208,398 shares of the company’s stock, valued at approximately $17,680,486.32. The trade was a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, March 4th, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The shares were sold at an average price of $71.06, for a total transaction of $390,830.00.
• On Wednesday, February 4th, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The stock was sold at an average price of $65.79, for a total transaction of $361,845.00.
• On Wednesday, January 7th, Carl Dambkowski sold 18,700 shares of Apogee Therapeutics stock. The stock was sold at an average price of $77.84, for a total transaction of $1,455,608.00.

Apogee Therapeutics Price Performance

Shares of NASDAQ APGE opened at $84.34 on Friday. Apogee Therapeutics Inc. has a fifty-two week low of $26.20 and a fifty-two week high of $85.94. The firm has a market capitalization of $5.86 billion, a P/E ratio of -19.99 and a beta of 1.02. The company’s 50 day simple moving average is $71.40 and its 200 day simple moving average is $66.01.

Apogee Therapeutics (NASDAQ:APGE) last issued its earnings results on Monday, March 2nd. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.02. Sell-side analysts expect that Apogee Therapeutics Inc. will post -3.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Apogee Therapeutics

Large investors have recently modified their holdings of the business. Rockefeller Capital Management L.P. bought a new position in shares of Apogee Therapeutics during the 4th quarter valued at about $25,000. ANTIPODES PARTNERS Ltd increased its stake in Apogee Therapeutics by 41.2% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock worth $33,000 after purchasing an additional 246 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Apogee Therapeutics during the 4th quarter worth approximately $37,000. Quantbot Technologies LP acquired a new stake in Apogee Therapeutics during the 3rd quarter worth approximately $96,000. Finally, Seven Fleet Capital Management LP bought a new position in Apogee Therapeutics in the fourth quarter valued at approximately $136,000. 79.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

APGE has been the topic of a number of recent analyst reports. Craig Hallum restated a “buy” rating and set a $116.00 target price on shares of Apogee Therapeutics in a report on Wednesday, January 7th. Canaccord Genuity Group upped their price target on Apogee Therapeutics from $89.00 to $130.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Apogee Therapeutics in a research report on Tuesday, December 9th. They issued a “buy” rating and a $103.00 price target on the stock. Mizuho boosted their price objective on shares of Apogee Therapeutics from $105.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, March 30th. Finally, Wall Street Zen downgraded shares of Apogee Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Apogee Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $110.79.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.